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Abstract 
Rationale: Myocardial infarction (MI) results in damaged heart tissue which can progress to severely reduce cardiac 
function, leading to death. Recent studies have injected dissociated, suspended cardiac cells into coronary arteries to 
restore function with limited results attributed to poor cell retention and cell death. Extracellular matrix (ECM) injected 
into damaged cardiac tissue sites show some promising effects. However, combined use of human cardiac ECM and 
cardiac cells may produce superior benefits to restore cardiac function.
Objective: This study was designed to assess use of new three‑dimensional human heart ECM‑derived scaffolds to 
serve as vehicles to deliver cardiac‑derived cells directly to damaged heart tissue and improve cell retention at these 
sites while also providing biomechanical support and attracting host cell recruitment.
Methods and Results: ECM‑derived porous protein scaffolds were fabricated from human heart tissues. These 
scaffolds were designed to carry, actively promote and preserve cardiac cell phenotype, viability and functional 
retention in tissue sites. ECM scaffolds were optimized and were seeded with human cardiomyocytes, cultured and 
subsequently implanted ex vivo onto infarcted murine epicardium. Seeded human cardiomyocytes readily adhered 
to human cardiac‑derived ECM scaffolds and maintained representative phenotypes including expression of cardio‑
myocyte‑specific markers, and remained electrically synchronous within the scaffold in vitro. Ex vivo, cardiomyocyte‑
seeded ECM scaffolds spontaneously adhered and incorporated into murine ventricle.
Conclusions: Decellularized human cardiac tissue‑derived 3D ECM scaffolds are effective delivery vehicles for human 
cardiac cells to directly target ischemic heart tissue and warrant further studies to assess their therapeutic potential in 
restoring essential cardiac functions.
Keywords: Scaffolds, Regeneration, Cellular transplantation, Cardiac ischemia, Cardiomyocytes, Viability, Tissue 
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Background
Ischemic heart disease is currently the leading cause of 
death in the United States. Yearly, ~525,000 Americans 
will experience their first myocardial infarction (MI) 
and 190,000 will have a recurrent attack [1]. During 
MI, blood flow to a section of the heart is cut off, sub-
sequently contributing to local acute tissue ischemia and 
the death of approximately one billion cardiomyocytes 
[2]. Furthermore, the resulting necrotic tissue acute 
zone is typically replaced by dense fibrous scar, imped-
ing cardiac tissue regeneration and restoration of normal 
heart function. Due to limited intrinsic repair potential 
exhibited by the heart, much research has been directed 
towards improved methods for cardiac tissue regenera-
tion. Towards this end, cell therapy strategies—includ-
ing stem cell delivery—are now actively developed, with 
some showing promising results for restoring cardiac 
function [3, 4]. Clinical trial data has shown a reduction 
in myocardial scarring, a degree of healthy myocardial 
regeneration, or an increase in left ventricular ejection 
fraction in response to post-infarction cell therapy [5–7]. 
However, cell survival, engraftment, and control of cell 
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differentiation state are major challenges associated with 
the local injection of cell populations for heart repair [8]. 
Additionally, cells injected after MI encounter a harsh 
environment that promotes apoptosis, and the majority 
of injected cells die within 4 days [9]. Furthermore, cells 
delivered through systemic circulation or coronary arter-
ies have low rates of localization to the infarcted myocar-
dium [9, 10], and it has been reported that only 10–15% 
of transepicardially injected cells are retained in the myo-
cardium [11]. The majority of cells are lost to filter organs 
such as the liver and spleen [12]. These limitations must 
be addressed to increase treatment efficacy.
Autologous human myoskeletal cell suspensions 
injected into human cardiac MI sites have produced 
spontaneous arrhythmias [13, 14]. This pathology plus 
the long-standing inability to retain sufficient amounts of 
injected cells in MI tissue sites has prompted increasing 
use of biomaterials-based approaches to such cardiac tis-
sue cellular therapeutic strategies. Notably, cell delivery 
modalities include gel-based injectable cell-containing 
carriers [15] and living cell sheets to retain cells at the 
injured site. The Okano group pioneered beating contig-
uous cardiomyocyte cell sheets for use as heart patches 
[16] and demonstrated their utility in porcine [17] 
and rat [18] models. Bel et  al. also used cell sheets, but 
found a multilayer construct with increased ECM con-
tent provides better efficacy [19]. Chein’s group isolated 
progenitors that could ultimately be used to create 3D 
viable cell constructs that could regenerate a single por-
tion of a damaged heart [20]. However, these groups have 
focused on cellular delivery, rather than on exploiting 
autologous extracellular matrix (ECM) either as a bulk-
ing agent or a therapeutic cell carrier. ECM proteins have 
also been used to regenerate damaged myocardium post-
MI. Cardiac ECM has significant influence in cardiac 
development, and undergoes several changes during car-
diac disease progression [21, 22]. ECM proteins provide 
essential biochemical and mechanical cues to guide cell 
differentiation and phenotype [23]. Although the influ-
ence of extracellular matrix in cardiac regeneration is 
not well understood, many studies now begin to examine 
this relationship. For example, ECM isolated from decel-
lularized skeletal and cardiac muscle has been shown to 
improve cardiomyocyte differentiation and maturation 
[24], and periostin was found to increase myocyte pro-
liferation and enhance cardiac repair [25]. Another study 
showed that isolated fetal cardiac ECM promoted myo-
cyte adhesion and expansion better than adult cardiac 
ECM [26]. Significantly, extracellular matrix materials 
have been used in a variety of cardiac tissue engineering 
approaches. For instance, decellularized cardiac ECM 
in the form of an injectable hydrogel has been shown to 
preserve post-MI cardiac function in preclinical animal 
studies [27, 28]. Furthermore, decellularized cardiac bio-
materials have been used as acellular patches for repair of 
ventricular defects in animal models [29, 30], and several 
groups are investigating use of cardiac ECM to promote 
cardiac phenotypes in 3-dimensional (3D) constructs in 
vitro [31–33]. These studies indicate that cardiac-derived 
extracellular matrix materials have a significant impact 
on heart regeneration. However, these 3D scaffolds 
are made of decellularized cardiac tissue or hydrogels, 
both of which have limited geometric and mechanical 
properties.
In addition to biochemical stimuli from ECM materi-
als, mechanical properties and scaffold geometry may 
be equally important for promoting mature cardiac tis-
sue. For instance, materials of appropriate stiffness 
(~10  kPa) [34] and materials patterned to promote car-
diomyocyte orientation [35] have both been reported to 
improve cardiomyocyte differentiation and maturation. 
Though cardiac ECM hydrogels have been researched, 
they inherently lack sufficient mechanical properties [36]. 
Furthermore, for 3D tissue engineering constructs, high 
scaffold porosity enables cell infiltration and transport 
of nutrients and wastes [34, 37]. However, decellularized 
ECM biomaterials have inherently fixed porosity (consti-
tuting the absent cells), density and geometry, dependent 
entirely upon the organ in which it was retrieved.
Although many decellularized extracellular matrix 
materials are clinically available, they are relatively lim-
ited in that their mechanical properties and porosity 
are dependent on the tissue of origin and these proper-
ties are not easily modified. Alloderm® and Matristem® 
are two such decellularized clinical biomaterials made 
from human dermis and porcine urinary bladder tissue, 
respectively [38]. The pores of these fibrous ECM materi-
als arise from the removal of the original cells, and the 
small size of these pores, on the order of 10 microns or 
less [39], limits cell infiltration [38]. CorMatrix ECM™, 
decellularized porcine small intestinal submucosa, used 
for pericardial and cardiac tissue repair [40], is also lim-
ited by its small pore size. Other approaches for 3D tissue 
engineering suffer from similar issues. Lyophilization of 
ECM materials, a process used to produce porous protein 
foams, leads to a wide distribution of pore sizes, ~10–
250 μm with an average around 70 μm [41]. Additionally, 
electrospun scaffolds have been shown to have small pore 
sizes that hinder cell infiltration [42]. Taken together, 
the limited porosity control of tissue engineering scaf-
folds, especially for decellularized biomaterials, limits 
recellularization into their interior and eventual homo-
geneous growth. Furthermore, many of the clinically 
available decellularized materials are not of human ori-
gin, and, importantly, none are composed of tissue-spe-
cific, cardiac-derived ECM, intuitively the most relevant 
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compilation of proteins for cardiac-specific regeneration 
and repair.
Based on these limitations of tissue engineering, fabri-
cation of allogeneic cardiac-derived extracellular matrix 
scaffolds with well-defined structure and large pores that 
allow for greater cell density should be both unique and 
highly advantageous for cardiac tissue engineering strate-
gies. Such scaffolds may be used to deliver cells directly 
to an injury site, which has shown efficacy [19], and to 
provide cells with a favorable microenvironment and bio-
chemical cues, improve cell survival and retention, and to 
ultimately promote improved myocardial regeneration. 
Importantly, efficacious scaffolds must be able to sup-
port viability in the presence of diffusion alone until host 
vascularization can occur. Otherwise, all implanted scaf-
folds will necrose prior to engraftment. Towards this aim, 
we have decellularized human myocardial tissue using a 
gentle decellularization procedure to maximally preserve 
endogenous protein content, created ECM scaffolds 
with a large, controlled, interconnected pore structure, 
and recellularized these scaffolds with human primary 
cardiac cells and human iPSC-derived cardiomyocytes. 
This complete, human heart-derived ECM carrier (1) uti-
lizes the intrinsic regenerative capacity of both ECM and 
cardiac cells in concert, (2) uniquely retains mechanical 
and biochemical features of native cardiac ECM, (3) can 
deliver many millions of viable synchronously beating 
cells directly to cardiac tissue sites, and (4) can support 




Human heart tissue from several donors was procured 
after consent under IRB numbers 35241 and 35242 from 
the University of Utah and frozen at −80°C until the 
decellularization process began. Heart tissue was pooled 
and decellularized using a gentle immersion decellu-
larization process, and handled in a biosafety cabinet 
throughout the purification process to maintain sterility. 
After thawing tissue overnight at 4°C, tissue was minced 
into pieces ~1 cm3 in size. Minced tissue was rinsed with 
sterile water (Baxter, Deerfield, USA) to remove excess 
blood and fluids. Next, tissue was blended in sterile water 
(blender model 7010S, Waring Commercial, Torrington, 
USA) to create a homogenous slurry. Soluble and insol-
uble portions of tissue were separated by centrifugation 
at 3,000 rcf and 40°C (Sorvall Legend XTR centrifuge, 
Thermo Fisher Scientific, Pittsburgh, USA). Following 
centrifugation, the supernatant was discarded, new ster-
ile water was added in a 1:4 pellet to water ratio, and the 
pellet was dispersed and mixed thoroughly. This slurry 
was centrifuged again, the water was exchanged, and 
water washes continued until the supernatant had mini-
mal color. Following water washes, the tissue was then 
washed three times in isopropyl alcohol (Sigma Aldrich, 
St Louis, USA), following the same procedure. Next the 
tissue was washed in 3 M NaCl (Sigma Aldrich); for this 
and the remaining washes, centrifugation was performed 
at 4°C. Tissue was then washed five times with 40 mg/ml 
sodium deoxycholate (SDC, Sigma Aldrich); with each 
SDC wash, the tissue was placed on an orbital shaker 
(model 980001, VWR, Radnor, USA) for at least 18  h 
before centrifugation. If after five SDC washes the SDC 
supernatant had color indicative of incomplete washing, 
additional SDC washes were performed until there was 
no additional color in the supernatant. Following SDC 
washes, tissue was washed again with 3  M NaCl, then 
with 100 U/ml DNase (Worthington Biochemical, Lake-
wood, USA) to aid DNA removal, and next with PBS (Life 
Technologies, Carlsbad, USA). Finally, the tissue prepara-
tion was washed ten times in sterile water. Before each 
new washing solution, the tissue was washed twice in 
sterile water to rinse out the old solution. The entire pro-
cess was ~10 days in duration with the majority of time 
taken by the SDC wash. The resulting insoluble material, 
mainly composed of extracellular matrix protein compo-
nents, was frozen in sterile water and lyophilized (Fre-
eZone 2.5, Labconco, Kansas City, USA), then stored at 
−20°C until use.
Prior to use in scaffold fabrication or submission for 
mass spectrometry, lyophilized decellularized cardiac tis-
sue was solubilized in sterile 0.1 M acetic acid (Thermo 
Fisher Scientific, Pittsburgh, USA) at a concentration of 
5 mg/ml. After sitting in acetic acid overnight at 4°C, the 
decellularized tissue was homogenized (Polytron 1200 E, 
Kinematica AG, Littau-Lucerne, Switzerland) for 5 min. 
The solution was kept on ice during homogenization to 
prevent denaturation at high temperature.
Scaffold fabrication
Porous ECM scaffolds were fabricated from decellular-
ized cardiac tissue using a sacrificial polycaprolactone 
(PCL) porous scaffold as a template. The PCL scaffold 
was generated as a template for the ECM protein and 
later dissolved away. To create the sacrificial porous 
scaffold, PCL (Sigma Aldrich) was dissolved in acetone 
(Sigma Aldrich) at 50°C at a concentration of 0.15 g/ml. 
Next, water was added dropwise to 8% of the total vol-
ume. The PCL/acetone/water solution was then mixed 
with the porogen NaCl, sieved to select for salt crystals 
between 425 and 500 µm (for stem cell and primary car-
diac cell ECM scaffolds) or <250 µm (for iCell iPSC car-
diomyocyte ECM scaffolds). This mixture was added to 
50  ml conical tubes (BD Biosciences, Franklin Lakes, 
USA) thoroughly mixed and centrifuged at 500  rcf and 
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35°C to create a uniform saturated salt suspension. The 
mixture was placed at −20°C to solidify, and the salt 
porogen was subsequently removed by immersion in 
excess water. The resulting PCL foam exhibits a well-
defined pore structure with larger pores formed by the 
salt porogen and smaller pores formed by water. These 
foams were cut to a thickness of 0.65–0.7 mm (stem cell 
and primary cardiac scaffolds) or 0.3 mm (for iPSC car-
diomyocyte scaffolds) using a Centaur Deli Slicer (model 
212, Lombard, USA). Sliced porous PCL scaffolds were 
cut with biopsy punches (Miltenyi, Bergisch Gladbach, 
Germany) into 3 mm diameter slices intended for further 
studies.
Decellularized and solubilized cardiac ECM was then 
coated onto these porous PCL scaffolds. PCL scaffolds 
were immersed in a turbid solution of ECM solubilized in 
0.1 M acetic acid. The PCL foam and solution were placed 
in a vacuum chamber (Space Saver Vacuum Desiccator, 
Bel-Art, Wayne, USA) to remove gas pockets and facili-
tate full penetration of the solution into the PCL pores. 
Once all air bubbles were eliminated, scaffolds were air 
dried in a biosafety cabinet, forming a single, contiguous 
coating. This process was repeated to create a total of five 
ECM coats. Following coating, the bulk PCL matrix was 
removed by dissolution in 95% acetone at 40°C for 2 days. 
Acetone was replaced twice daily. Scaffolds were then 
transferred into 95% ethyl alcohol (Decon Labs, King 
of Prussia, USA) and then slowly exchanged into sterile 
water using several serial solutions of decreasing ethanol 
content (70, 50, and 25% ethyl alcohol). Finally, the PCL-
free scaffolds were washed 10 times in sterile water. The 
resulting scaffolds, comprising porous, templated decel-
lularized cardiac tissue, were frozen in 100% water, lyo-
philized, sterilized with ethylene oxide gas (University of 
Utah Hospital, Salt Lake City, USA), and stored at −20°C 
until use.
Primary derived cardiac cells
Human hearts were collected after research consent was 
obtained, under approved institutional review board of 
the University of Utah, IRB numbers 35241 and 35242. 
Left ventricle tissue from multiple donor hearts was 
mechanically minced into 1  mm3 pieces and placed 
in Dulbecco’s phosphate buffered saline DPBS(–) for 
30 min. Minced tissue was placed into DPBS(–) contain-
ing 0.45  mg/ml collagenase (Worthington Biochemi-
cal Corp.) and 1  mg/ml pancreatin (Life Technologies, 
Carlsbad, USA). Digestion was carried out for 60 min at 
37°C with gentle shaking every 5  min. Equal volume of 
DPBS(–) containing 10% XcytePLUS™-Xenofree Media 
(iBiologics, Phoenix, USA) was added to the digestion, 
then filtered using a 100 µm filter. Filtered cells were then 
washed 3×  with DPBS(–) containing 10% XcytePLUS™ 
by centrifugation and plated into tissue culture plates 
(Nunc, Thermo Fisher Scientific, Pittsburgh, USA) for 
differential adhesion overnight at 5% CO2/37°C. After 
12  h, non-adherent cells were discarded and adherent 
cells, likely consisting of a heterogeneous mixture of car-
diomyocytes and fibroblasts, were passaged using TryplE 
(Life Technologies, Carlsbad, USA) and frozen till use 
using CryoStore CS10® (BioLife Solutions, Bothell, USA).
Induced pluripotent stem cell‑derived cardiomyocytes
Pure human iCell cardiomyocytes containing mono-
meric red fluorescent protein (RFP) expressed under con-
trol of the endogenous Myh6 promoter were purchased 
from Cellular Dynamics (Madison, USA) and cultured 
according to manufacturer’s instructions. Briefly, imme-
diately upon receipt, the vial of iCell cardiomyocytes 
was washed, cells were counted using a hemocytometer 
(Baxter, Deerfield, USA) and then resuspended at a con-
centration of 10 ×  106  cells/100  µl, which in our hands 
yielded 100% confluence (data not shown). Cells were 
seeded onto scaffolds (vide infra) and placed into iCell 
cardiac plating medium for 48 h at 37°C and 7% supple-
mental CO2. After 48  h, media was replaced with iCell 
cardiac maintenance media that was changed every 48 h 
throughout the duration of the experiment.
Scaffold seeding
Lyophilized and sterilized porous ECM scaffolds were 
added to a 50  ml conical tube containing cell suspen-
sions of 106 cells/100  l for primary cardiac cells (on our 
scaffolds and Matristem®, Acell, Columbia, USA), and 
107  cells/100  l for iPSC cardiomyocytes (on our scaf-
folds), and allowed to rehydrate for 10 min. During this 
time, a spatula was used to immerse the buoyant scaffolds 
continuously in the cell slurry. Air bubbles were removed 
to ensure homogeneous scaffold seeding; the vial cap was 
loosened and allowed to de-gas in a vacuum chamber for 
10 min, a sufficient time to eliminate air bubbles without 
removing all dissolved oxygen in the cell slurry. Six scaf-
folds per well were added to a 12-well plate (Nunc). After 
12 h non-adherent cells were discarded and adhered cells 
were cultured in iCell Cardiomyocyte media (cellular 
dynamics) for both iCell iPSC cardiomyocytes and pri-
mary cardiac cells. Media was changed every other day 
and cells were cultured in a 37 incubator with 5% supple-
mental CO2 for a maximum of 7 days.
Gross imaging and video
A Leica M165FC dissecting microscope equipped with 
a DFC425 camera and Leica Application Suite soft-
ware v3.8.0 was used to take bright-field and fluores-
cent images of the empty ECM scaffolds and Matristem® 
(Acell, Columbia, USA) and seeded ECM scaffolds on 
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explanted mouse heart, tissue, respectively. Videos of 
cell-seeded, beating ECM scaffolds were taken with an 
Olympus IX51microscope equipped with fluorescence 
and DP72 CCD camera and CellSens software v1.6.
Mass spectrometry
Sample preparation
Samples of decellularized tissue solubilized in 0.1 M ace-
tic acid were submitted to the University of Utah Health 
Sciences Center Mass Spectrometry and Proteomics 
Core (Salt Lake City, USA) for protein identification.
Digest of proteins in solution
Proteins from heart scaffolds were digested with TPCK-
modified trypsin (Promega). Trypsin (in 50 mM ammo-
nium bicarbonate) was added to the solution (adjusted to 
pH 7.9) to obtain a ratio of ~1–25 (enzyme to protein). 
Digest reactions were allowed to continue for overnight 
(at 37°C) for standard protein ID analyses.
Mass spectrometry
Peptides were analyzed using a nano-LC–MS/MS sys-
tem comprised of a nano-LC pump (Eksigent) and a 
LTQ-FT mass spectrometer (ThermoElectron Corpora-
tion, San Jose, CA, USA). The LTQ-FT is a hybrid mass 
spectrometer with a linear ion trap used typically for MS/
MS fragmentation (i.e. peptide sequence) and a Fourier 
transform ion-cyclotron resonance (FT-ICR) mass spec-
trometer used primarily for primary MS accurate mass 
measurement of peptide molecular ions. The LTQ-FT 
is equipped with a nanospray ion source (ThermoElec-
tron Corp.). Approximately 5–20 fmoles of tryptic digest 
samples were dissolved in 5% acetonitrile with 0.1% for-
mic acid and injected onto a C18 nanobore LC column 
for nano-LC–MS/MS and identification of peptides. The 
nanobore column was homemade [C18 (Atlantis, Waters 
Corp); 3  µm particle; column: 75  µm ID  ×  100  mm 
length] Atlantis dC18, 3 μm × 75 μm × 100 mm (Waters 
Corp.). A linear gradient LC profile was used to sepa-
rate and elute peptides, consisting of 5–70% solvent B in 
78 min with a flow rate of 350 nl/min (solvent B: 80% ace-
tonitrile with 0.1% formic acid; solvent A: 5% acetonitrile 
with 0.1% formic acid). The LTQ-FT mass spectrometer 
was operated in the data-dependent acquisition mode 
controlled by Xcalibur 1.4 software, in which the “top 10” 
most intense peaks observed in an FT primary scan (i.e. 
MS survey spectrum) are determined by the computer 
on-the-fly and each peak is subsequently trapped for MS/
MS analysis and peptide fragmentation (sequencing by 
collision-induced dissociation) in the LTQ linear ion trap 
portion of the instrument. Spectra in the FT-ICR were 
acquired from m/z 400 to 1,700 at 50,000 resolving power 
with about 3 ppm mass accuracy. The LTQ linear ion trap 
was operated with the following parameters: precursor 
activation time 30 ms and activation Q at 0.25; collision 
energy was set at 35%; dynamic exclusion width was set 
at low mass of 0.1 Da and high mass at 2.1 Da with one 
repeat count and duration of 10 s.
Mascot database searches
LTQ FT MS raw data files were processed to peak lists 
with BioworksBrowser 3.2 software (ThermoElectron 
Corp., San Jose, CA, USA). Processing parameters used 
to generate peak lists were as follows: precursor mass 
351–5,500  Da; grouping was enabled allowing 5 inter-
mediate MS/MS scans; precursor mass tolerance 5 ppm, 
minimum ion count in MS/MS was set to 15, and mini-
mum group count was set to 1. Resulting DTA files from 
each data acquisition file were merged and the data file 
was searched for identified proteins against the NCBI 
human taxonomy sub-database, using MASCOT search 
engine (Matrix Science Ltd.; version 2.2.1; in-house 
licensed). Searches were done with tryptic specificity, 
allowing two missed cleavages and a mass error toler-
ance of 5  ppm in MS spectra (i.e. FT-ICR data) and 
0.5 Da for MS/MS ions (i.e. LTQ linear ion trap). Vari-
able modification included in the searches was oxidation 
of methionine, histidine and tryptophan residues. Iden-
tified peptides were generally accepted only when the 
MASCOT ion score value exceeded 20. Peptides identi-
fied in the MASCOT search results were all further vali-
dated by manual confirmation of molecular ions from 
the FTMS spectra and assigned fragment ions from the 
corresponding MS/MS spectra.
Surface coatings with decellularized tissue
Glass chamber slides (Chamber slide system 154534, 
Nunc) were coated with decellularized cardiac tissue sol-
ubilized in 0.1 M acetic acid, diluted to 1.5 mg/ml.
Chamber slides (Chamber slide system 154534, Nunc) 
were coated by incubation with cardiac ECM protein sol-
ubilized in 0.1 M acetic acid (diluted to 1.5 mg/ml) over-
night at 4°C and subsequently washed three times with 
PBS. Coated chamber slides were air-dried and sterilized 
by UV exposure in biosafety cabinet for 30 min.
Mouse heart explant and in situ scaffold placement
Care of animals was in accordance with institutional 
guidelines. Necropsies were performed on 6 C57/BL6 
mice routinely sacrificed by veterinary staff for other 
purposes. Hearts were aseptically removed and the 
pericardium was dissected away. ECM scaffolds seeded 
with viable cardiomyocytes and cultured for 6 days were 
overlaid onto the left ventricle portion of the freshly iso-
lated hearts. Once placed, scaffolds remained untouched 
on this cardiac tissue surface for 3 min. After this time, 
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forceps were used to attempt to displace the scaffold 
from the surface by sliding the scaffolds along heart wall.
Confocal imaging
For viability analysis, cell-seeded ECM scaffolds were 
stained with Calcein AM and PI (Invitrogen, Carls-
bad, USA) according to manufacturer’s instructions 
and imaged on their external surfaces and through their 
center zones. To image cell viability within scaffold cent-
ers, the scaffolds were cut transversely and placed cut-
side down onto a glass slide and imaged (a second slide 
was held perpendicular to the first glass slide to stabilize 
the cut scaffold). Confocal images from 3 scaffolds and 3 
images per scaffold were collected in the red and green 
channels. Using ImageJ (imagej.nih.gov), the number of 
green (Calcein AM) cells were compared to the number 
of red (PI) cells in each frame to obtain percent cell via-
bility on day 7. The average and standard deviation (SD) 
from 9 images are displayed below.
To determine cell distribution, cells were fixed in 4% 
paraformaldehyde (Affymetrix, Cleveland, USA) and 
labeled with and 4′,6-diamidino-2-phenylindole (DAPI, 
Invitrogen) and rhodamine-phalloidin (Life Tech-
nologies, Carlsbad, USA) according to manufacturer’s 
instructions. Rabbit anti-cardiac troponin T (Abcam, 
Cambridge, USA 1:200), rabbit anti-connexin 43 (Abcam 
1:200) and rabbit anti-N-cadherin (Abcam 1:200) were 
used with secondary antibody Donkey anti-rabbit-488 
(Invitrogen, 1:500).
Cells within scaffolds were imaged on a Nikon AR1 
confocal microscope. For all images, a z-series compris-
ing 7 sections, 20  μm thick were stacked into a single 
image (spanning 140 μm total). A Prairie multi-photon 
confocal microscope was used to image the second har-
monic signal of collagen from both the explanted native 
mouse heart and ECM scaffold placed onto the mouse 
heart.
Scanning electron microscopy
Scaffolds were fixed in 4% paraformaldehyde and 2% 
glutaraldehyde and post-fixed in 2% osmium tetroxide, 
dehydrated through a series of ethanol washes, and dried 
with hexamethyldisilazane. The scaffolds were then sput-
ter-coated with gold (30 s at 40 microamps) using a Pelco 
SC-7 autosputter coater and imaged with a SEM (FEI 
Quanta 600 FEG scanning electron microscope) under 
high vacuum.
Optical action potential
After 6 days of culture, ECM scaffolds (3 mm in diameter, 
0.3 mm thick) with a porogen size of 250 µm seeded with 
iCell cardiomyocytes were used for optical action poten-
tial and microelectrode array recordings. iCell media was 
replaced with a voltage-dependent dye solution (Infrared 
dye USD DI-4ANBDQBS diluted 1:1,000 in iCell media) 
for 7 min. After 7 min, media was replaced with dye-free 
iCell media. All media used was pre-warmed to 37°C. 
Scaffolds were transferred to an imaging chamber filled 
with iCell media on a Nikon microscope. Only 70  µl of 
media was added to keep scaffold moist, but prevent it 
from floating. A 50 W heat lamp was used 4 inches away 
from the imaging chamber to keep the cells at 37°C (a 
thermometer was placed in the imaging chamber to 
ensure a constant temperature was maintained). The heat 
lamp was turned off only during direct image capture.
To reduce movement artifacts, cardiomyocyte seeded 
scaffolds were treated with 10  µM blebbistatin (recon-
stituted in DMSO at 16.7  mM) diluted in HEPES to 
uncouple cardiomyocyte motion. Scaffolds were allowed 
to sit for 15 min for the uncoupler to take effect prior to 
imaging.
Microelectrode array recordings
Also on day 6, another set of cell-seeded ECM scaf-
folds was analyzed using a custom-built microelectrode 
array apparatus (kindly donated by A. Moreno, Univer-
sity of Utah). iCell cardiomyocyte seeded scaffolds were 
recorded in 37°C iCell media. To confirm the electrical 
acuity of the cell-seeded ECM scaffolds, 1 µM isoproter-
enol (Hospira, Lake Forest, USA) was added and the scaf-
folds were subsequently recorded.
Results
Purified heart ECM comprises numerous proteins
Mass spectrometry analysis performed on purified and 
solubilized heart ECM proteins indicates that the highest 
concentration of proteins include collagen I, II, II, IV, and 
VI and laminin. Results are displayed in Figure  1a. The 
entire list of proteins detected is listed in Additional file 
1: Figure S1.
Heart matrix in 2D and 3D supports cardiac phenotype
Soluble heart ECM protein was coated onto glass slides 
and primary-derived cardiac cells from explanted hearts 
were cultured. Cells displayed non-specific staining of 
heart markers including connexin 43, troponin, and 
N-cadherin (Figure  1b–d). The lack of robust cardio-
myocyte staining indicates a larger population of cardiac 
derived fibroblasts, progenitor cells, or other stromal 
cells and not cardiomyocytes were present. This indi-
cated that a pure population of cardiomyocytes would 
need to be implemented. However, the protein did show 
that it supported stromal cardiac cell growth, which was 
promising. Human heart-derived ECM was also used to 
create 3D porous scaffolds and subsequently seeded with 
primary-derived cardiac cells. Scaffolds were co-labeled 
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with actin, DAPI, and Connexin 43 to show cell distribu-
tions (Figure 1e–g).
3D porous ECM scaffolds posses large pores compared 
to decellularized tissue
Using the unique method described for processing ECM 
protein on sacrificial porous PCL templates, 3D matrices 
made of human heart protein with pore sizes of 425–
500 µm were generated. These pore sizes were far larger 
than those seen in commercially available Matristem® 
decellularized porcine urinary bladder matrix (UBM, 
Figure 2).
Large ECM scaffold pores enable substantial cell viability
Pore sizes >425  µm allowed detection of viable seeded 
left ventricular primary cells throughout the 0.75  mm 
scaffold thickness after 7  days of culture, 62.15%  ±  SD 
5.89% viability (Figure  3a–d). Heart ECM-derived scaf-
folds maintained more viable cells and improved cell 
distribution through a greater thickness (Figure  3c–d). 
Compared to commercially available Matristem® scaf-
folds (Figure 3e) To optimize cell–cell contacts and yield 
a very high density of seeded cardiomyocytes, scaffolds 
of 0.3 mm thickness with pore sizes of 250 µm were cre-
ated. A z-stack of iCell cardiomyocytes spanning 500 µm 
is seen within these 3D constructs (Figure 3f–h).
iCell iPSC cardiomyocytes in 3D ECM scaffolds maintain 
electrical competence
Seeded iCell iPSC-derived human cardiomyocytes within 
the ECM scaffolds were electrically competent and main-
tained long action potentials (Figure 4a, b) characteristic 
of human cardiomyocytes [43].
Day 2 post-seeding, iCell iPSC cardiomyocytes within 
scaffolds began to beat. By day 6, cardiomyocytes began 
beating synchronously both in 2D (Figure 4c; Additional 
file 2: Video 1) and in 3D and were able to contract the 
scaffold in unison (Figure  4d, e; Additional files 3, 4: 
Video 2A, B). This synchrony decayed after day 6 likely 
as cardiac fibroblasts proliferated on the ECM scaffold 
(data not shown). Still shots of videos taken are shown in 
Figure 4c–e.
iPSC cardiomyocytes within scaffolds also responded 
to Isoproterenol by increasing the amplitude and fre-
quency of their beats (Figure  4f, g). Irregularities in 
beat rate could be due to incomplete confluency, which 
could allow subpopulations of cardiomyocytes to affect 
the consistency of the field potentials detected with the 
microelectrode array. Videos of this pharmacologically 
altered beat frequency can be found in Additional files 5, 
6: Videos 3A and B.
Cardiomyocyte adhesion behavior on ECM scaffolds
Cardiomyocytes readily attach to the scaffold surface as 
illustrated by scanning electron micrograph images (Fig-
ure 5a–c). Interestingly when the cell-seeded scaffold was 
placed on freshly (within 1–2  min of death) explanted 
murine heart surfaces, the ECM scaffolds spontaneously 
adhered to the murine tissue within 3 min. Once the scaf-
folds adhered, they could not be directionally moved or 
readjusted on the mouse heart tissue surface (Figure 5d–
g). When cell-seeded scaffolds were placed on murine 
hearts preserved in saline at 4°C for 24  h, the scaffolds 
did not adhere and the scaffolds could easily be removed 
(data not shown). This suggests there is an active cell 
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Figure 1 Proteins in cardiac ECM and cells. a Summary of primary proteins found in human heart ECM via mass spectrometry. Confocal images 
of human primary left ventricle cells cultured in 2D on purified human heart ECM stained for b connexin 43 and co‑labeled with actin and DAPI, c 
troponin, and d N‑cadherin and in 3D scaffolds made of human heart ECM expressing e connexin 43 and labeled with f phalloidin, and g DAPI.
Page 8 of 15Holt‑Casper et al. J Transl Med  (2015) 13:194 
which could enable the scaffolds to adhere in vivo with-
out the need for exogenous methods for adhesion. Fig-
ure  5d shows a second harmonic optical image of the 
scaffold adhered to the mouse heart. This optical image 
shows the misalignment of fiber directionality between 
the heart (*) and scaffold (s).
Discussion
It is commonly believed progressive heart failure follow-
ing MI is associated with adverse cardiac remodeling. 
Several approaches exist to promote healthy cardiac 
remodeling and bulk up the infarcted wall. One approach 
is the use of hydrogels made of synthetic polymers [44] 
or animal derived ECM [27, 28] that are injected into 
infarcted areas. This treatment modality shown to help 
prevent scar expansion and wall thinning, increases 
left ventricular ejection fraction, and improves overall 
cardiac function [27, 28, 44]. To provide more relevant 
signaling cues and avoid undesired foreign body reac-
tions, this study focused on ECM protein, rather than 
synthetic polymers. Specifically cardiac ECM, pursued 
by several groups [27, 28, 30], was utilized to provide the 
most relevant biochemical signaling cues and proteins 
specific for heart structural and physiological function, 
such as collagen and laminin (Figure 1a, Additional file 1: 
Figure  S1). Moreover, to facilitate further clinical trans-
lation and reduce potential risks associated with xeno-
geneic proteins such as viral disease transmission and 
non- homologous signaling, we utilized purified human 
heart ECM protein, rather than animal-sourced ECM. 
There are over 3,000 hearts in the US that are not used 
for transplant, but are used for tissue and valves. A sin-
gle heart can be utilized to create scaffolds that can patch 
dozens of hearts. Thus, human heart ECM scaffolds are 
1 mm1 mm





500 µm 1 mm500 µm
Figure 2 Microscopic analysis of scaffold porosity. Dissecting microscope images of a top view and b cross section of Matristem® and a b top view 
and c and d cross sections of our human heart ECM scaffolds. SEM images of e Matristem®, and our PCL template scaffolds in f high and g low 
magnification.
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a viable option for scaffold generation clinically. Impor-
tantly, this study not only uses human ECM, but also 
utilizes a novel method to form human heart ECM into 
perhaps unparalleled highly porous, voluminous scaf-
folds with strikingly interconnected, uniform pores. The 
human heart ECM purified in this study was solubilized 
and coated onto glass surfaces and supported primary 
heart cell phenotype (Figure 1b–d), showing promise as 
a biomaterial.
However, ECM alone as a biomaterial has so far been 
shown to be insufficient in addressing degenerative car-
diac tissue or restoring damaged cardiac tissue to func-
tional form. More effective treatment strategies for 
cardiac repair will likely comprise tissue-specific ECM 
and incorporated, viable cells capable of maintaining and 
sustaining tissue-context-dependent phenotypes and 
functions. Cell therapies of diverse forms have shown 
limited efficacy in regenerating damaged heart tissue, in 
large part by providing regenerative signaling cues [4]; 
however, only a small portion of these delivered cells 
make it to or remain within the compromised tissue zone 
in vivo [11]. A cellular delivery vehicle that better ensures 
tissue site-, context-, and function-specific localization of 
cells, their viability, phenotype and effective integration is 
required. The heart-derived, porous 3D-templated ECM 











Figure 3 Viability of cardiac cells within scaffolds. Confocal images of top views of a viable (green Calcein AM) and b dead (red propidium iodide) 
left ventricular primary cells. Cross‑sectional views of c live and d dead left ventricular primary cells. Cross‑sectional view of live (green) and dead 
(red) left ventricular primary cells in Matristem® (e). f–h Confocal image views of 30 stacked z‑slices of human cardiomyocytes within human ECM 
scaffolds showing homogeneous distribution. Cardiomyocytes express red fluorescent protein under control of endogenous Myh6 promoter.
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cellular support, exploiting xenogeneic-free purified 
human heart ECM with cardiac cells.
Cell sheets have been utilized to deliver functional cells 
to defects in the heart, but the viability of these monolay-
ers limits sheet thickness and subsequently cell number 
and accompanying ECM [45]. Other groups have also 
pursued fibroblast-grown ECM, however these con-
structs are still limited to 70  μm-thick, and increasing 
their thickness results in poor cell viability due to poor 















































Figure 4 Electrical competence of cardiac cells within scaffolds. a Fluorescent image of voltage sensitive dye and corresponding b optical action 
potential of human cardiomyocytes within 3D human heart ECM scaffold. Still images of beating cardiomyocytes in c 2D culture, and in 3D scaffolds 
seen d fluorescently and e in Brightfield. Corresponding videos can be found in Additional files 2, 3, 4: Video 1, 2A, 2B, respectively. Cardiomyocytes 
maintained sufficient intercellular connections that enabled the scaffolds to contract as a single unit. Microelectrode array recordings of field 
potentials from human cardiomycoyte‑seeded scaffolds f before and g after isoprenaline (Videos are found in Supplementary Videos 3A and 3B, 
respectively). Addition of isoprenaline heightened the amplitude and increased the beat rate 27%.
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those pursued in this study, are an option to maximize 
the number of cells and ECM protein that can be deliv-
ered to a heart defect, thereby overcoming limitations 
encountered with current cardiac repair approaches.
Three primary methods for generating analogous 3D 
porous scaffolds from ECM materials are commonly 
employed including electrospinning, lyophilization, and 
decellularization. However, all three methods yield lim-
ited pore sizes, thereby decreasing the number of cells 
that are capable of being delivered using the scaffold. 
Electrospinning generally provides matrix pore sizes 
of 25–100  µm [47], lyophilization yields pore sizes of 
10–250  µm [41] that can be highly heterogeneous [48], 
and decellularized constructs only have pore sizes of the 
absent cells (e.g., 10’s of microns). Cells entomb them-
selves in extracellular matrix [49], so retroactively add-
ing back cells to such decellularized, tight matrix voids 
(Figure  2) is highly inefficient and nearly impossible to 
control well. Cell infiltration of these scaffolds can be 
severely limited with small matrix pore sizes. Brown et al. 
reported poor cell infiltration into both decellularized 
porcine urinary bladder matrix (UBM) and small intesti-
nal submucosa (SIS) [38]. Commercially available decel-
lularized UBM, Matristem® compared in this study with 
our ECM porous scaffolds showed both poor cell infiltra-
tion (limited to ~100 µm penetration distances from the 
outer surfaces) and resulting viability (Figure  3). Phipps 
et al. seeded cells onto electrospun PCL, collagen I, and 
hydroxyapatite composite matrices and only were able to 
achieve ~100  µm of cell penetration through the thick-
ness of their scaffolds [42]. Another group using poly 
polyglycolic acid (PGA) woven mesh scaffolds had far 
fewer cells within the center of their scaffolds even with 
circulating media [50, 51]. This same group began using 
commercially available lyophilized collagen sponges that 
still only contained viable cells within 100 µm thick layer 
around the periphery of their scaffolds [51].
The novel human heart ECM-derived porous scaf-
folds described in this study are capable of breaking 
this apparent 100  µm viability barrier. Possessing large 
interconnected pores, they enable complete penetration 
throughout 750  µm thick constructs, 7.5 times greater 
than Matristem® (Figure  3). The scaffolds in this study 
also demonstrate nearly twice as many viable cells as pre-
viously reported PGA scaffolds [52]. Moreover they sup-
port homogenous cell distribution that maintains high 
cell viability (62.15% ± SD 5.89%) out 7 days (Figure 3), 
even under static cell culture conditions—without need 
for circulating media or complex perfusion systems. This 
feat is of paramount importance as an implanted con-
struct must be able to maintain viability until host vascu-
larization can occur. 7 days has shown to be a sufficient 






20 μm 100 μm 100 μm
Figure 5 Attachment of cardiac cells on scaffolds. False colored scanning electron microscope images of human cardiomyocytes on human heart 
extracellular matrix scaffolds in a high, b medium, and c low magnifications. d Two photon microscope image of a scaffold overlaid over a murine 
heart. The second harmonic of the collagen fibrils are visualized. Dissecting microscope images (representative) of a human cardiomyocyte‑seeded 
human ECM scaffold on an adult mouse heart: e shows scaffold in brightfield, f shows autofluorescent scaffold on a lesser autofluorescent mouse 
heart, and g shows red florescent cardiomyocytes within the scaffold. Scaffolds spontaneously fused to mouse heart within 3 min.
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time period for vascularization to occur [53]. The scaf-
folds developed in this study support a clinically relevant 
number of cells for a clinically relevant period of time. 
Importantly, the diameter of the scaffold has no affect on 
viability (data not shown), enabling larger constructs that 
cover larger surface areas of the heart to be employed. 
The ECM scaffolds developed in this study utilized 
porous polymer templates as sacrificial scaffolds with 
controlled geometry and density, a process commonly 
used in metallurgy, enabling precise control over final 
ECM protein structure and porosity. These sacrificial 
PCL scaffolds are endowed with fine control over pore 
sizes using porogens. Salt porogens were used to create 
polymer matrix pore sizes ranging from 250 to 500 µm, 
far larger than those commonly seen in known commer-
cial ECM materials (Figure 2). After porogen removal, the 
porous polymeric scaffolds were coated with solubilized, 
purified human heart ECM, using air-drying processes 
to bond serially deposited ECM layers together. This 
process of drying creates strong, pure ECM protein scaf-
folds without the crosslinking utilized by many current 
ECM scaffold technologies [39, 41]. Exogenous chemical 
methods crosslink ECM proteins [54] in manners dis-
tinct from native lysyl oxidase crosslinking of native pro-
teins [55]. Chemical crosslinking alters the mechanical 
properties of the scaffold, reducing elasticity and com-
pliance, and importantly reducing degradative capacity 
[54]. Highly degradable ECM will better expedite tissue 
regeneration and replacement of scaffold ECM by native 
ECM, a feature readily afforded by ECM scaffolds lack-
ing chemical crosslinking. Chemical crosslinking also 
increases the body’s innate foreign body response, result-
ing in a highly oxidative cellular environment often lethal 
to both exogenous and endogenous cells, thus inhibit-
ing regeneration [56]. These known deleterious effects 
of the host foreign body response have limited some use 
of scaffolds [19]. Scaffolds absent of chemical crosslink-
ing are afforded faster degradation and reduced foreign 
body reaction potential, and likely improved regenerative 
capacity compared to commercially available and com-
monly used chemically cross-linked ECM scaffolds.
This study utilized heterogeneous primary cardiac cells 
and homogenous iPSC human cardiomyocytes seeded 
in novel human heart derived ECM scaffolds. Our pre-
vious work has successfully cultured stem cells on simi-
larly constructed adipose-derived scaffolds [57], which 
may also be pursued for cardiac regeneration therapy. 
Matrix pore sizes of 425–500  µm and monolith thick-
ness of 0.75 mm for primary heterogeneous cardiac cells 
provided reliable cell viability and phenotypes (Figure 3). 
However, this heterogeneous population of cells pos-
sessed a large amount of cardiac fibroblasts and too few 
functional cardiomyocytes to enable a functional beating 
construct. iPSC derived cardiomyocytes were then uti-
lized as a pure enough population to potentially enable 
synchronous beating within the scaffolds. To optimize 
sufficient cell densities for cardiac synchronization, scaf-
folds with pore sizes of 250 microns and thicknesses of 
0.3 mm were employed. These matrix fabrication condi-
tions enabled both cell seeding and maintenance of suf-
ficient iPSC cardiomyocyte densities to mechanically 
contract the entire ECM scaffold in unison (Figure  4d, 
e; Additional files 3, 4: 2A, B). Though contracting 
occurred, subpopulations of cardiomyocytes were still 
present in the scaffold that likely affected the complete 
unity of the cells within the scaffold. Lack of complete 
confluency and the presence of multiple pacemaker 
cells driving the preparation could cause irregular beat-
ing. Future work will strive to achieve total confluence 
and uniformity. The iPSC cardiomyocytes seeded within 
these same ECM scaffolds displayed electrical compe-
tence and maintained long action potentials (Figure  4a, 
b) consistent with human cardiomyocyte action poten-
tials [43, 58]. Though great variability with iPSCs in cul-
ture has been seen ranging from 250 to 1,500 ms [59].
These cells also responded to beta-adrenergic agonist 
and cardiac chronotrope, Isoproterenol, as expected by 
increasing the amplitude and frequency of their beats in 
response to this pharmacology (Figure  4f, g; Additional 
file 5, 6: 3A, B). This increase in amplitude could be due 
to an increase in recruitment of additional beating cells 
or the reduction in action potential duration dispersion 
due to faster beating. Similar tests utilizing isoproterenol 
have also been utilized by other groups to prove cardio-
myocyte functionality [51, 60]. These metrics indicate 
that both pacemaker cells and cardiomyocytes main-
tain many of their responsive mechanisms within these 
ECM scaffolds. Future studies will analyze potential 
arrhythmia formation post isoproterenol and how syncy-
tium structure and anisotropic force development affect 
functionality.
A microscopic analysis of seeded cells on these ECM 
scaffolds shows cells maintain several points of adhesion 
to the ECM scaffold (Figure  5a–c). Interestingly, when 
these cardiomyocyte-seeded scaffolds were placed on 
freshly explanted mouse hearts, the entire scaffold spon-
taneously adhered to the mouse ventricle tissue within 
minutes, making it impossible to remove the scaffold 
with forceps without tearing it (Figure  5d–g). The sec-
ond harmonic optical image from a two-photon micro-
scope highlights differences in collagen fibril orientation 
between the scaffold and murine heart tissue (Figure 5d). 
Scaffolds with aligned collagen fibrils will likely beat 
more efficiently. Future work will be to create scaffolds 
with a more linear pore structure to encourage linear 
collagen fibril and cardiomyocyte alignment. Electrical 
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stimulation has also be used to increase both collagen 
fibril alignment and ultrastructure of tissue engineered 
heart scaffolds, a technique employed by Vunjak-Nova-
kovic’s group that resulted in constructs with greater 
ultrastructure similarity to native heart tissue [61].
Conclusions
We have developed novel human derived scaffolds with 
sufficient pore size to enable the seeding and survival of 
a critical number of human cardiomyocytes to maintain 
cardiac synchrony. This construct acts as a cell deliv-
ery vehicle that can serve as a patch to treat ischemic 
heart tissue and directly target cells to damaged tissue 
sites. Furthermore these constructs are made entirely 
of human heart protein and human cells, and grown in 
a completely xeno-free system. Our process eliminates 
risk of xeno-disease transmission, optimizes regenerative 
capacity, and provides an expedited therapy for clinical 
translation.
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